Literature DB >> 23939260

Striatal dopamine depletion induces forelimb motor impairments and disrupts forelimb movement representations within the motor cortex.

Emily K Plowman1, Nagheme J Thomas, Jeffrey A Kleim.   

Abstract

While limb motor deficits of Parkinson's disease are well characterized, the effects of striatal dopamine depletion on the motor cortex is poorly understood. We therefore aimed to 1) examine the effects of striatal dopamine depletion on forelimb function and cortical motor map topography and 2) explore potential relationships between forelimb function and cortical movement representations in an animal model of PD. Twenty-four male Long Evans rats were randomized to control or 6-hydroxydopamine (6-OHDA) groups. Animals in the 6-OHDA group underwent four unilateral 6-OHDA infusions into the striatum to induce striatal dopamine depletion. Four weeks later, animals were tested on a comprehensive battery of behavioral limb motor tasks followed by intracortical microstimulation to derive high-resolution topographic maps of forelimb movement representations. Standard tyrosine hydroxylase (TH) immunohistochemistry was performed and near infrared densitometry analysis utilized to assess TH depletion. Unilateral striatal dopamine depletion induced significant reductions in limb motor function that were reflected neurophysiologically as a reduction in cortical forelimb movement representations. Voluntary forelimb use, pasta handling, sunflower seed manipulation, and forelimb motor maps were all significantly impaired in 6-OHDA animals. A positive correlation was observed between forelimb function and motor map size, as well as two negative correlations between TH depletion with 1) motor map size and 2) forelimb function. The results clearly show how dysfunction within the basal ganglia thalamocortical loop resulting from nigrostriatal dopamine depletion disrupts corticospinal function.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 23939260      PMCID: PMC7236202          DOI: 10.3233/JPD-2011-11017

Source DB:  PubMed          Journal:  J Parkinsons Dis        ISSN: 1877-7171            Impact factor:   5.568


  27 in total

1.  CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury.

Authors:  T Schallert; S M Fleming; J L Leasure; J L Tillerson; S T Bland
Journal:  Neuropharmacology       Date:  2000-03-03       Impact factor: 5.250

Review 2.  Parkinson's disease--Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment.

Authors:  Daniel Weintraub; Cynthia L Comella; Stacy Horn
Journal:  Am J Manag Care       Date:  2008-03       Impact factor: 2.229

3.  The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies.

Authors:  D Eidelberg; J R Moeller; V Dhawan; J J Sidtis; J Z Ginos; S C Strother; J Cedarbaum; P Greene; S Fahn; D A Rottenberg
Journal:  Mov Disord       Date:  1990       Impact factor: 10.338

4.  Metabolic activity of cerebellar and basal ganglia-thalamic neurons is reduced in parkinsonism.

Authors:  Anne-Sophie Rolland; Maria-Trinidad Herrero; Virginia Garcia-Martinez; Merle Ruberg; Etienne C Hirsch; Chantal François
Journal:  Brain       Date:  2007-01       Impact factor: 13.501

5.  Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.

Authors:  O Rascol; D J Brooks; E R Brunt; A D Korczyn; W H Poewe; F Stocchi
Journal:  Mov Disord       Date:  1998-01       Impact factor: 10.338

6.  Dopaminergic response in Parkinsonian phenotype of Machado-Joseph disease.

Authors:  Carsten Buhmann; Alexandra Bussopulos; Matthias Oechsner
Journal:  Mov Disord       Date:  2003-02       Impact factor: 10.338

Review 7.  Update on models of basal ganglia function and dysfunction.

Authors:  Mahlon DeLong; Thomas Wichmann
Journal:  Parkinsonism Relat Disord       Date:  2009-12       Impact factor: 4.891

8.  Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity.

Authors:  Fredric P Manfredsson; Nihal Tumer; Benedek Erdos; Tessa Landa; Christopher S Broxson; Layla F Sullivan; Aaron C Rising; Kevin D Foust; Yi Zhang; Nicholas Muzyczka; Oleg S Gorbatyuk; Philip J Scarpace; Ronald J Mandel
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

9.  Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate.

Authors:  T Z Aziz; D Peggs; M A Sambrook; A R Crossman
Journal:  Mov Disord       Date:  1991       Impact factor: 10.338

10.  The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism.

Authors:  H Bergman; T Wichmann; B Karmon; M R DeLong
Journal:  J Neurophysiol       Date:  1994-08       Impact factor: 2.714

View more
  4 in total

1.  Differential sensitivity of cranial and limb motor function to nigrostriatal dopamine depletion.

Authors:  Emily K Plowman; Nicholas Maling; Benjamin J Rivera; Krista Larson; Nagheme J Thomas; Stephen C Fowler; Fredric P Manfredsson; Rahul Shrivastav; Jeffrey A Kleim
Journal:  Behav Brain Res       Date:  2012-09-24       Impact factor: 3.332

2.  Developmental and interventional plasticity of motor maps after perinatal stroke.

Authors:  Sarah Y Zhang; Matthew S Jeffers; Diane C Lagace; Adam Kirton; Gergely Silasi
Journal:  J Neurosci       Date:  2021-06-01       Impact factor: 6.167

3.  Botulinum Neurotoxin A Injected Ipsilaterally or Contralaterally into the Striatum in the Rat 6-OHDA Model of Unilateral Parkinson's Disease Differently Affects Behavior.

Authors:  Veronica A Antipova; Carsten Holzmann; Oliver Schmitt; Andreas Wree; Alexander Hawlitschka
Journal:  Front Behav Neurosci       Date:  2017-06-21       Impact factor: 3.558

4.  Repeated Intrastriatal Botulinum Neurotoxin-A Injection in Hemiparkinsonian Rats Increased the Beneficial Effect on Rotational Behavior.

Authors:  Alexander Hawlitschka; Carsten Holzmann; Andreas Wree; Veronica Antipova
Journal:  Toxins (Basel)       Date:  2018-09-11       Impact factor: 4.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.